IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms

被引:7
作者
Habermehl, Gabriel K. [1 ]
Nakashima, Megan O. [1 ]
Cotta, Claudiu, V [1 ]
机构
[1] Cleveland Clin, RJ Tomsich Pathol & Lab Med Inst, Cleveland, OH 44195 USA
关键词
IgA; Myeloma; Prognosis; Genetic complexity; Plasma cell; MULTIPLE-MYELOMA; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; MANAGEMENT; DIAGNOSIS;
D O I
10.1016/j.anndiagpath.2019.151449
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The characteristics of the IgA plasma cell neoplasms are not clearly reported in the literature. The main goal of this study is to examine IgA plasma cell neoplasms (PCN) and to compare them to IgG lesions. After at least 5 years from the identification of an M protein, 98 cases were selected, the presentation and clinical evolution of 45 IgA neoplasms were compared to 43 cases of IgG gammopathies. The classification at presentation as monoclonal gammopathy of undermined significance (MGUS)-22 of 45 IgA and 20 of 43 IgG (49 vs 46%), plasma cell myeloma (PCM)-22 of 45 IgA and 22 of 43 IgG (49 vs 51%) and smoldering PCM (SPCM)-1 each (2% for both) was essentially identical. No solitary plasmacytomas were identified. At presentation, IgA patients were younger (66.5 +/- 11.3 vs. 69.2 +/- 10.7 years), less likely to have bone lesions (12/45 vs 18/43, p < 0.14) or immunoparesis (51% vs. 63%), differences statistically insignificant. Cases with normal fluorescence in-situ hybridization (FISH) results, 27% for IgA vs 61% for IgG (p < 0.037) were statistically different. The IgA patients had worse survival (80 vs 108 months median IgA vs IgG, p < 0.013), difference not detectable in the first 5 years, but substantial after 10. In conclusion, poorer long-term survival and increased genomic complexity by FISH are characteristics of IgA PCNs.
引用
收藏
页数:6
相关论文
共 24 条
[1]   IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases [J].
Angelova, Evgeniya A. ;
Li, Shaoying ;
Wang, Wei ;
Bueso-Ramos, Carlos ;
Tang, Guilin ;
Medeiros, L. Jeffrey ;
Lin, Pei .
HUMAN PATHOLOGY, 2019, 84 :321-334
[2]   IgA Kappa/IgA Lambda Heavy/Light Chain Assessment in the Management of Patients With IgA Myeloma [J].
Boyle, Eileen M. ;
Fouquet, Guillemette ;
Guidez, Stephanie ;
Bonnet, Sarah ;
Demarquette, Helene ;
Dulery, Remy ;
Herbaux, Charles ;
Noel, Marie Pierre ;
Manier, Salomon ;
Schraen, Suzanna ;
Onraed, Brigitte ;
Faucompre, Jean-Luc ;
Hennache, Bernadette ;
Petillon, Marie Odile ;
Mathiot, Claire ;
Avet-Loiseau, Herve ;
Facon, Thierry ;
Harding, Stephen J. ;
Moreau, Philippe ;
Leleu, Xavier .
CANCER, 2014, 120 (24) :3952-3957
[3]   Heavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region [J].
Calderon, Boris .
CLINICAL CHEMISTRY, 2015, 61 (02) :317-318
[4]   Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004 [J].
Dores, Graca M. ;
Landgren, Ola ;
McGlynn, Katherine A. ;
Curtis, Rochelle E. ;
Linet, Martha S. ;
Devesa, Susan S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) :86-94
[5]   Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials [J].
Drayson, Mark ;
Begum, Gulnaz ;
Basu, Supratik ;
Makkuni, Sudhaker ;
Dunn, Janet ;
Barth, Nicola ;
Child, J. Anthony .
BLOOD, 2006, 108 (06) :2013-2019
[6]   Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany [J].
Eisele, Lewin ;
Duerig, Jan ;
Huettmann, Andreas ;
Duehrsen, Ulrich ;
Assert, Roland ;
Bokhof, Beate ;
Erbel, Raimund ;
Mann, Klaus ;
Joeckel, Karl-Heinz ;
Moebus, Susanne .
ANNALS OF HEMATOLOGY, 2012, 91 (02) :243-248
[7]   Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms [J].
Gao, Qi ;
Yellapantula, Venkata ;
Fenelus, Maly ;
Pichardo, Janine ;
Wang, Lu ;
Landgren, Ola ;
Dogan, Ahmet ;
Roshal, Mikhail .
MODERN PATHOLOGY, 2018, 31 (06) :881-889
[8]   MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia [J].
Jimenez, C. ;
Sebastian, E. ;
Chillon, M. C. ;
Giraldo, P. ;
Hernandez, J. Mariano ;
Escalante, F. ;
Gonzalez-Lopez, T. J. ;
Aguilera, C. ;
de Coca, A. G. ;
Murillo, I. ;
Alcoceba, M. ;
Balanzategui, A. ;
Sarasquete, M. E. ;
Corral, R. ;
Marin, L. A. ;
Paiva, B. ;
Ocio, E. M. ;
Gutierrez, N. C. ;
Gonzalez, M. ;
Miguel, J. F. San ;
Garcia-Sanz, R. .
LEUKEMIA, 2013, 27 (08) :1722-1728
[9]   Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays [J].
Katzmann, Jerry A. ;
Willrich, Maria A. V. ;
Kohlhagen, Mindy C. ;
Kyle, Robert A. ;
Murray, David L. ;
Snyder, Melissa R. ;
Rajkumar, Vincent ;
Dispenzieri, Angela .
CLINICAL CHEMISTRY, 2015, 61 (02) :360-367
[10]   IgM Multiple Myeloma Pathologic Evaluation of a Rare Entity [J].
King, Rebecca L. ;
Howard, Matthew T. ;
Hodnefield, Janice M. ;
Morice, William G. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 140 (04) :519-524